Skip to main content

Maria Llorian Salvador

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Maria Llorian Salvador

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Terapia inmunomoduladora para la retinitis pigmentosa

IP: Maria Llorian Salvador
Collaborators: -
Funding agency: Fundación Lucha contra la Ceguera FUNDALUCE
Funding: 30000
Reference: FUNDALUCE/2024/LLORIAN
Duration: 12/09/2025 - 12/09/2027

Retinal and cognitive dysfunction in type 2 diabetes

IP: Rafael Simó Canonge
Collaborators: Maria Llorian Salvador, Miriam Izquierdo Sans
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 152348.46
Reference: 2022 BP 00067
Duration: 01/04/2024 - 31/03/2027

Topical administration of sitagliptin in experimental models of diabetic retinopathy and glaucoma: delving into mechanisms of action and changing the therapeutic positioning (“Sit@Retina”).

IP: Rafael Simó Canonge
Collaborators: Maria Llorian Salvador
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 321250
Reference: PID2022-138544OB-I00
Duration: 01/09/2023 - 31/08/2026

Ministerio de Ciencia

Diabetis i metabolisme

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Rosario Pardo Diaz, Angel Michael Ortiz Zúñiga, Andreea Ciudin Mihai, Fiorella Ximena Palmas Candia, Ana Maria Ortiz de Urbina Olive, Monica Sanchez Bartres, Lorena Ramos Pérez, Marc Rivas Agudo, Diabetis i metabolisme, Anna Casteras Román, Alejandra Planas Vilaseca, Betina Biagetti Biagetti, Diabetis i metabolisme, Mercè Abad Martín, Marta Comas Martinez, Hugo Ramos Abellan, Rosa Burgos Peláez, David Sabater Martínez, Olga Simó Servat, Patricia Bogdanov Baruj, Maria Llorian Salvador, Enzamaría Fidilio Meli
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00655
Duration: 01/01/2022 - 30/06/2025

Related news

The publications update the pharmacological management guideline for obesity and its complications and present the first European comprehensive management guideline for patients with obesity treated with medications.

The study evaluates elecoglipron and shows improvements in glycemic control and body weight compared with placebo.

The study is expected to contribute to the identification of new therapeutic targets and the development of nutritional strategies to improve health.

Related professionals

Karla Alejandra  Cameron  Veas

Karla Alejandra Cameron Veas

Tècnic de recerca
Commercial and Academic Clinical Research
Read more
Marco Inzitari

Marco Inzitari

Head of group
Research on Aging, Frailty and Transitions in Barcelona
Read more
Maria Nazarena Pizzi

Maria Nazarena Pizzi

Senior researcher
Cardiovascular Diseases
Read more
Danilo Rivas Nicolls

Danilo Rivas Nicolls

Predoctoral researcher
Donation and transplantation of organs, tissues and cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.